Small cell lung cancer in never-smokers

Torres-Durán, María; Ruano-Raviña, Alberto; Kelsey, Karl T.; Parente-Lamelas, Isaura; Provencio, Mariano; Leiro-Fernández, Virginia; Abal-Arca, José; Montero-Martínez, Carmen; Vidal-García, Iria; Pena, Carolina; Castro‐Añón, Olalla; Golpe-Gómez, Antonio; Martínez, Cristina; Guzmán-Taveras, Rosirys; Mejuto-Martí, María José; Fernández-Villar, Alberto; Barros-Dios, Juan Miguel

doi:10.1183/13993003.01524-2015

Cited by 36 publications

(19 citation statements)

References 29 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Never-smokers had clearly shorter survival (8.3 months vs. 12.3 months in former smokers and 12.2 months in active smokers). This survival data were similar to other studies, even in limited-stage disease [19].…”

Section: Discussionsupporting

confidence: 92%

Trends in response rate and survival in small cell lung cancer patients between 1997 and 2017.

Lattuca-Truc

Levra

Ruckly

et al. 2018

JCO

View full text Add to dashboard Cite

J'aimerais tout d'abord remercier les membres du jury, c'est un honneur pour moi de vous présenter le fruit de mon travail.Au Pr MORO SIBILOT, c'est une grande fierté de vous avoir en tant que président du jury, j'aimerais vous remercier de m'avoir transmis cette passion de l'oncologie thoracique avant même le début de mon internat dans votre service, c'est une vraie chance d'avoir pu travailler et apprendre à vos côtés ! Au Pr DEGANO, merci pour votre présence dans ce jury. Je n'ai malheureusement pas eu l'occasion de travailler avec vous mais j'ai pu assister à plusieurs de vos cours de pneumologie, c'était très intéressant et instructif, j'admire vos qualités d'orateur certaines.Au Dr DELAFOSSE, merci d'avoir répondu présente. C'est un plaisir de vous présenter ce travail, qui j'espère vous aura intéressée ! Au Dr TOFFART, merci d'avoir accepté d'encadrer ce travail de thèse. J'ai pris beaucoup de plaisir à relever ce challenge avec toi, c'était très enrichissant. Merci pour ta disponibilité, ton aide précieuse et ton professionnalisme. Très fier d'avoir pu partager cette aventure avec toi.A toute l'équipe de pneumologie du CHU Grenoble Alpes.Pr PISON, merci pour toutes ces années passées avec vous. Je vous suis très reconnaissant de m'avoir permis d'effectuer mon internat dans les meilleures conditions, aux côtés de personnes remarquables au quotidien. Merci pour votre bienveillance et votre transmission de savoir.

show abstract

Section: Discussionsupporting

confidence: 92%

Trends in response rate and survival in small cell lung cancer patients between 1997 and 2017.

Lattuca-Truc

Levra

Ruckly

et al. 2018

JCO

View full text Add to dashboard Cite

show abstract

“…In a 2016 study of SCLC, María et al published a result that the prognosis of non-smokers was as poor as that of smokers [29]. A previous work reported that the tobacco-attributed proportion was increasing in men, but low, and decreasing in women in Chinese population [30]. Similar to preceding results, few female patients were smokers in our cohort (2.7%).…”

Section: Discussionsupporting

confidence: 86%

Clinical features and outcome of small cell lung cancer in female patients: a large-cohort retrospective study

Hou¹,

Wang²,

Li³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Currently, female small cell lung cancer (SCLC) incidence has been increasing. However, there have been few large database-based studies on female patients with SCLC. In this study, we used Surveillance, Epidemiology, and End Results (SEER) database to describe the clinical characteristics and prognosis of female SCLC patients.Methods: SCLC patients from the SEER database between 1973 and 2015 were included. Gender, age, race, stage, tumor size, and metastasis status were included in our study. Clinical characteristics were analyzed among females and males with SCLC. Survival analyses were conducted with log-rank tests and Cox proportional hazard models.Results: A total of 18234 patients were extracted from SEER database. 50.2% of the whole SCLC patients were females. Compared with males, females were less likely to be Asians, carry bigger size of tumor, have later TNM stage, and have distant metastases (P < 0.05). Gender proved to be an independent prognostic factor for SCLC patients (CSS:HR:1.105;95% CI: 1.068 1.143; P < 0.001; OS: HR, 1.120;95% CI: 1.084 1.158; P < 0.001). Female patients presented more favorable survival than male patients (Median OS/CSS:11 vs. 9 months, P < 0.001). Our results confirmed that age≥65, white race, later stage, tumor size ≥ 50mm and distant metastases were all associated with poor prognosis in female patients.Conclusions: Female gender is associated with more favorable outcome of SCLC. For females, patients who are senile, white people, and have poorer pathological features were associated with a shorter OS, which need to be more circumspectly treated in clinical practice.

show abstract

“…In a study conducted by Torres-Duran et al 19 patients with SCLC who were never smokers were followed. Almost all were female patients ( n = 18), with a median age of 75 years (9). Similarly, another study conducted at the Memorial Sloan Kettering Cancer Center (MSKCC) which included 19 never smoker patients with de novo SCLC, reported a predisposition in the female population under 65 years (20).…”

Section: Discussionmentioning

confidence: 99%

“…In terms of clinical behavior, patients with extensive SCLC and a positive smoking history have shorter overall survival, despite the younger age compared to their non-smoker counterparts (6, 7). However, two reports from Korea and Spain have yielded contradictory results indicating a favorable association with survival outcomes for smoker patients and a detrimental effect in the never/ever smokers (8, 9). Molecular characteristics also tend to be different in the two patient subgroups.…”

Section: Introductionmentioning

confidence: 99%

Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP)

et al. 2019

View full text Add to dashboard Cite

Objectives: Lung cancer is a heterogeneous disease. Presentation and prognosis are known to vary according to several factors, such as genetic and demographic characteristics. Small-cell lung cancer incidence is increasing in never-smokers. However, the disease phenotype in this population is different compared with patients who have a smoking history. Material and Methods: To further investigate the clinical and genetic characteristics of this patient subgroup, a cohort of small cell lung cancer patients was divided into smokers ( n = 10) and never/ever-smokers ( n = 10). A somatic mutation profile was obtained using a comprehensive NGS assay. Clinical outcomes were compared using the Kaplan-Meier method and Cox proportional models. Results: Median age was 63 years (46–81), 40% were men, and 90% had extended disease. Smoker patients had significantly more cerebral metastases ( p = 0.04) and were older ( p = 0.03) compared to their non-smoker counterparts. For never/ever smokers, the main genetic mutations were TP53 (80%), RB1 (40%), CYLD (30%), and EGFR (30%). Smoker patients had more RB1 (80%, p = 0.04), CDKN2A (30%, p = 0.05), and CEBPA (30%, p = 0.05) mutations. Response rates to first-line therapy with etoposide plus cisplatin/carboplatin were 50% in smokers and 90% in never/ever smokers ( p = 0.141). Median overall survival was significantly longer in never smokers compared with smokers (29.1 months [23.5–34.6] vs. 17.3 months [4.8–29.7]; p = 0.0054). Never/ever smoking history (HR 0.543, 95% CI 0.41–0.80), limited-stage disease (HR 0.56, 95% CI 0.40–0.91) and response to first-line platinum-based chemotherapy (HR 0.63, 95% CI 0.60–0.92) were independently associated with good prognosis. Conclusion: Our data supports that never/ever smoker patients with small-cell lung cancer have better prognosis compared to their smoker counterparts. Further, patients with never/ever smoking history who present with small-cell lung cancer have a different mutation profile compared with smokers, including a high frequency of EGFR, MET , and SMAD4 mutations. Further studies are required to assess whether the differential mutation profile is a consequence of a diverse pathological mechanism for disease onset.

show abstract

Small cell lung cancer in never-smokers

Cited by 36 publications

References 29 publications

Trends in response rate and survival in small cell lung cancer patients between 1997 and 2017.

Trends in response rate and survival in small cell lung cancer patients between 1997 and 2017.

Clinical features and outcome of small cell lung cancer in female patients: a large-cohort retrospective study

Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP)

Contact Info

Product

Resources

About